Hyundai Bioscience Co. Ltd (048410) - Net Assets
Based on the latest financial reports, Hyundai Bioscience Co. Ltd (048410) has net assets worth ₩111.98 Billion KRW (≈ $75.89 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩129.10 Billion ≈ $87.49 Million USD) and total liabilities (₩17.12 Billion ≈ $11.60 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Hyundai Bioscience Co. Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩111.98 Billion |
| % of Total Assets | 86.74% |
| Annual Growth Rate | 2.41% |
| 5-Year Change | 79.84% |
| 10-Year Change | 507.9% |
| Growth Volatility | 63.53 |
Hyundai Bioscience Co. Ltd - Net Assets Trend (2002–2025)
This chart illustrates how Hyundai Bioscience Co. Ltd's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Hyundai Bioscience Co. Ltd to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Hyundai Bioscience Co. Ltd (2002–2025)
The table below shows the annual net assets of Hyundai Bioscience Co. Ltd from 2002 to 2025. For live valuation and market cap data, see market value of Hyundai Bioscience Co. Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩110.73 Billion ≈ $75.04 Million |
+180.76% |
| 2024-12-31 | ₩39.44 Billion ≈ $26.73 Million |
-12.88% |
| 2023-12-31 | ₩45.27 Billion ≈ $30.68 Million |
-22.26% |
| 2022-12-31 | ₩58.24 Billion ≈ $39.47 Million |
-5.42% |
| 2021-12-31 | ₩61.57 Billion ≈ $41.73 Million |
+20.20% |
| 2020-12-31 | ₩51.22 Billion ≈ $34.71 Million |
+9.01% |
| 2019-12-31 | ₩46.99 Billion ≈ $31.84 Million |
+16.07% |
| 2018-12-31 | ₩40.48 Billion ≈ $27.44 Million |
+31.06% |
| 2017-12-31 | ₩30.89 Billion ≈ $20.93 Million |
+69.59% |
| 2016-12-31 | ₩18.21 Billion ≈ $12.34 Million |
-25.97% |
| 2015-12-31 | ₩24.60 Billion ≈ $16.67 Million |
+9.43% |
| 2014-12-31 | ₩22.49 Billion ≈ $15.24 Million |
+3.13% |
| 2013-12-31 | ₩21.80 Billion ≈ $14.78 Million |
+15.38% |
| 2012-12-31 | ₩18.90 Billion ≈ $12.81 Million |
+33.31% |
| 2011-12-31 | ₩14.17 Billion ≈ $9.61 Million |
-55.82% |
| 2010-12-31 | ₩32.08 Billion ≈ $21.74 Million |
-18.36% |
| 2009-12-31 | ₩39.30 Billion ≈ $26.63 Million |
-21.96% |
| 2008-12-31 | ₩50.36 Billion ≈ $34.13 Million |
-13.54% |
| 2007-12-31 | ₩58.24 Billion ≈ $39.47 Million |
+243.64% |
| 2006-12-31 | ₩-40.55 Billion ≈ $-27.48 Million |
-203.11% |
| 2005-12-31 | ₩39.33 Billion ≈ $26.65 Million |
-35.47% |
| 2004-12-31 | ₩60.94 Billion ≈ $41.30 Million |
-10.83% |
| 2003-12-31 | ₩68.34 Billion ≈ $46.32 Million |
+6.65% |
| 2002-12-31 | ₩64.08 Billion ≈ $43.43 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hyundai Bioscience Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4168969842000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩152.42 Billion | 137.65% |
| Total Equity | ₩110.73 Billion | 100.00% |
Hyundai Bioscience Co. Ltd Competitors by Market Cap
The table below lists competitors of Hyundai Bioscience Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Anhui Wanyi Science and Technology Co Ltd
SHG:688600
|
$599.25 Million |
|
TomTom NV
AS:TOM2
|
$599.31 Million |
|
Ashot Ashkelon Industries Ltd
TA:ASHO
|
$599.72 Million |
|
China Catalyst Holding Co. Ltd. A
SHG:688267
|
$599.73 Million |
|
Recticel
BR:RECT
|
$598.73 Million |
|
NOVA Technology Corporation Limited
SHE:300921
|
$598.69 Million |
|
Momentum Group AB (publ)
ST:MMGR-B
|
$598.53 Million |
|
Jiangsu Yike Food Group Co.Ltd
SHE:301116
|
$598.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hyundai Bioscience Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 39,438,422,420 to 110,726,343,110, a change of 71,287,920,690 (180.8%).
- Net loss of 22,128,347,680 reduced equity.
- New share issuances of 84,258,269,460 increased equity.
- Other factors increased equity by 9,157,998,910.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-22.13 Billion | -19.98% |
| Share Issuances | ₩84.26 Billion | +76.1% |
| Other Changes | ₩9.16 Billion | +8.27% |
| Total Change | ₩- | 180.76% |
Book Value vs Market Value Analysis
This analysis compares Hyundai Bioscience Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.98x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 15.30x to 7.98x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩601.23 | ₩9200.00 | x |
| 2017-12-31 | ₩948.39 | ₩9200.00 | x |
| 2018-12-31 | ₩1200.73 | ₩9200.00 | x |
| 2019-12-31 | ₩1356.38 | ₩9200.00 | x |
| 2020-12-31 | ₩1426.28 | ₩9200.00 | x |
| 2021-12-31 | ₩1592.73 | ₩9200.00 | x |
| 2022-12-31 | ₩1467.61 | ₩9200.00 | x |
| 2023-12-31 | ₩1137.28 | ₩9200.00 | x |
| 2024-12-31 | ₩495.22 | ₩9200.00 | x |
| 2025-12-31 | ₩1152.93 | ₩9200.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hyundai Bioscience Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -629.12%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.18x
- Recent ROE (-19.98%) is below the historical average (-11.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 9.92% | 1.46% | 1.91x | 3.55x | ₩-55.71 Million |
| 2007 | 3.27% | 1.63% | 1.14x | 1.77x | ₩-3.92 Billion |
| 2008 | 10.44% | 4.42% | 1.36x | 1.74x | ₩221.61 Million |
| 2014 | -13.82% | -10.75% | 0.88x | 1.46x | ₩-5.36 Billion |
| 2015 | 2.89% | 1.75% | 0.94x | 1.76x | ₩-1.75 Billion |
| 2016 | -44.31% | -22.35% | 0.68x | 2.93x | ₩-9.89 Billion |
| 2017 | 3.94% | 3.81% | 0.65x | 1.60x | ₩-1.87 Billion |
| 2018 | 6.47% | 8.38% | 0.58x | 1.33x | ₩-1.43 Billion |
| 2019 | 1.63% | 2.55% | 0.48x | 1.35x | ₩-3.93 Billion |
| 2020 | -16.80% | -68.79% | 0.14x | 1.80x | ₩-13.73 Billion |
| 2021 | -32.57% | -216.97% | 0.11x | 1.31x | ₩-26.21 Billion |
| 2022 | -27.14% | -201.33% | 0.12x | 1.16x | ₩-21.63 Billion |
| 2023 | -32.03% | -152.92% | 0.18x | 1.17x | ₩-19.03 Billion |
| 2024 | -17.57% | -46.04% | 0.22x | 1.72x | ₩-10.87 Billion |
| 2025 | -19.98% | -629.12% | 0.03x | 1.18x | ₩-33.20 Billion |
Industry Comparison
This section compares Hyundai Bioscience Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $447,138,029,819
- Average return on equity (ROE) among peers: -6.15%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hyundai Bioscience Co. Ltd (048410) | ₩111.98 Billion | 9.92% | 0.15x | $598.77 Million |
| ORIENTBIO Inc. (002630) | $44.21 Billion | 0.00% | 0.54x | $72.49 Million |
| Green Cross (005250) | $1.85 Trillion | 1.30% | 0.98x | $342.58 Million |
| Green Cross Holdings Preference Shares (005257) | $1.88 Trillion | -2.88% | 0.99x | $3.26 Million |
| Pharmicell (005690) | $86.44 Billion | 7.32% | 0.15x | $579.46 Million |
| GeneOne Life Science Inc (011000) | $29.41 Billion | -40.45% | 0.68x | $51.80 Million |
| HLB Co. Ltd (028300) | $18.60 Billion | 0.00% | 1.06x | $4.45 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $36.31 Billion | 4.18% | 0.71x | $16.87 Million |
| Seoulin Bioscience Co.Ltd (038070) | $45.30 Billion | 4.03% | 0.46x | $30.03 Million |
| iNtRON Biotechnology Inc (048530) | $30.24 Billion | -28.88% | 0.51x | $59.56 Million |
About Hyundai Bioscience Co. Ltd
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.